

**Table 1: Study Characteristics**

Study	Design	Centre	Country	Sample size, n	Type of atrial arrhythmia	Mapping system	AF ablation	Blanking period	AAD during blanking period	Follow-up period	AADs during follow-up period	Arrhythmia detection method
Kim et al. 2021 <sup>22</sup>	RCT	Multicentre	South Korea	366	Paroxysmal AF	CARTO EnSite NavX	PVI	3 months	Yes	3.4 years (median)	Yes/no	ECG Holter monitor
Lee et al. 2019 <sup>23</sup>	Retrospective	Single-centre	Taiwan	139	Paroxysmal AF Persistent AF Long-standing persistent AF	EnSite NavX	PVI ± linear ablation/CFAE ablation/SVCI	3 months	Yes	21 ± 9 months	Yes/no	ECG Holter monitor
Mesquita et al. 2018 <sup>24</sup>	Retrospective	Multicentre	Portugal	822	Paroxysmal AF Persistent AF Long-standing persistent AF	CARTO EnSite NavX	PVI	3 months	Yes	24 months	Yes/no	ECG Holter monitor Event recorder
Pontoppidan et al. 2009 <sup>14</sup>	RCT	Multicentre	Denmark	149	Paroxysmal AF Persistent AF	CARTO	PVI ± linear ablation	3 months	Yes	12 months	Yes/no	ECG Holter monitor

*AADs = antiarrhythmic drugs; CFAE = complex fractionated atrial electrograms; PVI = pulmonary vein isolation; RCT = randomized controlled trial; SVCI = superior vena cava isolation.*

**Table 2: Patient Characteristics**

Study	Group	Sample size	Male sex	Age (years)	AF			Comorbid					Echocardiography		
					AF duration, months	Paroxysmal AF	CHA <sub>2</sub> DS <sub>2</sub> -VASc score	HF	HT	Stroke	CAD	DM	LVEF, %	LAD, mm	LAVI, mL/m <sup>2</sup>
Kim et al. 2021 <sup>22</sup>	PVI + CTI ablation	183	122 (66.7)	57.3 ± 11.2	NA	122 (100.0)	1.3 ± 1.3	3 (1.6)	79 (43.2)	5 (2.7)	NA	19 (10.4)	63.4 ± 6.7	39.4 ± 5.5	NA
	PVI	183	127 (69.4)	59.4 ± 10.1	NA	127 (100.0)	1.4 ± 1.2	4 (2.2)	77 (42.1)	9 (4.9)	NA	21 (11.5)	63.5 ± 5.3	38.9 ± 5.7	NA
Lee et al. 2019 <sup>23</sup>	PVI + CTI ablation	57	39 (68.4)	60.1 ± 10.0	29.0 ± 11.0	36 (63.2)	1.9 ± 1.4	8 (14.0)	37 (64.9)	5 (8.8)	NA	9 (15.8)	64.9 ± 11.0	39.7 ± 5.1	NA
	PVI	82	45 (54.9)	57.8 ± 11.0	21.0 ± 12.0	77 (93.9)	1.6 ± 1.3	1 (1.2)	40 (48.8)	6 (7.3)	NA	16 (19.5)	68.4 ± 9.2	36.0 ± 5.6	NA
Mesquita et al. 2018 <sup>24</sup>	PVI + CTI ablation	411	289 (70.3)	59.0 ± 2.5	NA	259 (63.0)	2.0 ± 0.4	NA	197 (47.9)	14 (3.4)	21 (5.1)	30 (7.3)	NA	NA	57.3 ± 3.5
	PVI	411	286 (69.6)	59.0 ± 2.4	NA	262 (63.7)	2.0 ± 0.4	NA	190 (46.2)	24 (5.8)	20 (4.9)	35 (9.5)	NA	NA	55.3 ± 3.0
Pontoppidan et al. 2009 <sup>14</sup>	PVI + CTI ablation	73	54 (74.0)	56.0 ± 8.0	78.0 ± 62.6	38 (52.1)	NA	16 (21.9)	21 (28.8)	NA	3 (4.1)	8 (11.0)	60.0 ± 10.0	48.0 ± 7.0	NA
	PVI	76	52 (68.4)	56.0 ± 8.0	54.6 ± 48.7	42 (55.3)	NA	16 (21.1)	35 (46.1)	NA	2 (2.6)	9 (11.8)	64.0 ± 9.0	46.0 ± 6.0	NA
Overall		1476	1014/1476 (68.7)	58.5 ± 10.8	43.0 ± 112.3	963/1476 (65.2)	1.7 ± 2.9	48/654 (7.3)	676/1476 (45.8)	63/1327 (4.7)	46/971 (4.7)	147/1476 (10.0)	64.0 ± 20.7	41.3 ± 39.1	56.3 ± 28.7

*CAD = coronary artery disease; CHA<sub>2</sub>DS<sub>2</sub>-VASc = congestive heart failure, hypertension, age ≥75 years, diabetes, prior stroke or transient ischaemic attack, vascular disease, age 65–74 years, sex class; CTI = cavotricuspid isthmus; DM = diabetes; HF = heart failure; HT = hypertension; LAD = left atrial diameter; LAVI = left atrial volume index; LVEF = left ventricular ejection fraction; NA = not available; PVI = pulmonary vein isolation.*